Skip to main content

Table 1 Duration of H2 treatment and lab studies of 4 patients

From: Hydrogen(H2) treatment for acute erythymatous skin diseases. A report of 4 patients with safety data and a non-controlled feasibility study with H2 concentration measurement on two volunteers

  chemistry hematology
GOT GPT γ-GPT T-BIL CRP WBC RBCx104 Plateletx104
Case 1 : 6 days
At the beginning 23 58 96 0.7 1.51 7800 462 32.2
4 days after 16 27 66 0.4 1.89 7800 430 36.8
9 days after (3 days after resumption) 20 22 63    10600 431 52.8
22 days after, (16 days After resumption) 17 12 45   0.19 8000 440 51.6
  chemistry hematology
GOT GPT γ-GPT T-BIL CRP WBC RBCx10 4 Plateletx10 4
Case 2:19 days
At the beginning 33 58 253 0.6 8.27 10200 367 29.1
7 days after 20 57 244   8.71 18800 297 20.1
10 days after 27 59 233   9.35 37000 348 3.8
2 weeks after 29 46 210 1.9 6.53 11900 288 1.9
18 days after 19 35 152 1.6 5.81 11200 258 4.6
3 weeks after 15 22 79   8.64 17700 310 24.2
  chemistry hematology
GOT GPT γ-GPT T-BIL CRP WBC RBCx10 4 Plateletx10 4
Case 3 : 2hrs
At the beginning 22 25 28    4500 432 13.6
45 days after (45 days after completion) 19 20 25 0.4 0.24 4500 439 15.5
  chemistry hematology
GOT GPT γ-GPT T-BIL CRP WBC RBC (万) Plateletx10 4
Case 4 : 3 days
At the begining 25 35 342   1.31 18000 396 30.6
2 days after 34 36 286   0.65 21900 381 26
5 days after (2 days after completion) 60 117 300   1.91 13200 409 11.7
  1. Administration of H2 did not change physiological parameters and did not cause significant deterioration of the blood chemistry such as for liver and kidney function, although some of these patients already had severe abnormalities before the H2 treatment such as thrombocytopenia of case 2.